Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC announces publication of case study results describing reductions in multiple lipid parameters for individual Hyperlipidemic patients switched to Vascepa


Wednesday, 11 Jun 2014 07:00am EDT 

Amarin Corporation PLC:Publication of retrospective analysis of patient cases that examined effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza  (omega-3-acid ethyl esters) capsules, a mixture of omega fatty acids.Says to Vascepa  (icosapent ethyl) capsules, the only pure-EPA prescription omega-3 product, to potentially achieve better outcomes in triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels.1 During studied period of 14 patients switched to Vascepa experienced reductions in levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C).Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.Effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. 

Company Quote

2.2
 +0.00%
4 Aug 2015